The Department of Veterans Affairs (VA) National Acquisition Center awarded a $9,494,690.00 Indefinite Delivery Contract (IDC) to Cipla USA Inc., a foreign-owned, for-profit pharmaceutical company, to supply Ambrisentan tablets. The contract has a base period of one year from April 1, 2021 to March 31, 2022, with four one-year option periods.
Ambrisentan is a specialty drug that requires enrollment in the Ambrisentan Shared Risk Evaluation and Mitigation Strategy (REMS) program. As such, the prime contractor must be an Ambrisentan REMS Consortium member and able to sponsor government outpatient pharmacies as authorized distributors. The contract aims to provide an uninterrupted supply of Ambrisentan 5mg and 10mg tablets to the VA and Federal Bureau of Prisons. Deliveries will be made through the VA's Pharmaceutical Prime Vendor program. This pre-solicitation was communicated through FedBizOpps and the awarded contract was established in a commercial item format under FAR Part 12.
Generated 2/19/25, 9:06 AM